Inflammatory Markers and Adverse Outcomes in Chronic Kidney Disease

NCT01974713 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2530

Last updated 2017-09-01

No results posted yet for this study

Summary

Longitudinal cohort of patients with chronic kidney disease followed in 3 kidney centers in Ontario. The goal is to determine whether and how rates of renal disease progression are affected by inflammatory markers, FGF23 levels, and genetic polymorphisms

Conditions

Sponsors & Collaborators

  • Institute of Kidney Lifescience Technologies

    lead OTHER

Principal Investigators

  • Paul Y Tam, MD · Kidney Life Science Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2016-04-30
Completion
2017-07-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01974713 on ClinicalTrials.gov